Irene M Ghobrial

List of Publications by Citations

284 papers	6,277 citations	41 h-index	75 g-index
318 ext. papers	8,091 ext. citations	5 avg, IF	5.87 L-index

#	Paper	IF	Citations
284	Ibrutinib in previously treated Waldenstrm's macroglobulinemia. *New England Journal of Medicine*, **2015**, 372, 1430-40	59.2	617
283	CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. *Blood*, **2009**, 113, 4341-51	2.2	354
282	Genomic complexity of multiple myeloma and its clinical implications. *Nature Reviews Clinical Oncology*, **2017**, 14, 100-113	19.4	267
281	Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. *Blood*, **2012**, 119, 5782-94	2.2	234
280	Engineered nanomedicine for myeloma and bone microenvironment targeting. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10287-92	11.5	204
279	The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. *Blood*, **2020**, 135, 1912-1915	2.2	195
278	Response assessment in Waldenstrm macroglobulinaemia: update from the VIth International Workshop. *British Journal of Haematology*, **2013**, 160, 171-6	4.5	173
277	Prognostic role of circulating exosomal miRNAs in multiple myeloma. *Blood*, **2017**, 129, 2429-2436	2.2	161
276	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. *Blood*, **2014**, 123, 4120-31	2.2	150
275	Myeloma as a model for the process of metastasis: implications for therapy. *Blood*, **2012**, 120, 20-30	2.2	139
274	Bone marrow niches in haematological malignancies. *Nature Reviews Cancer*, **2020**, 20, 285-298	31.3	134
273	Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrm's macroglobulinemia. *Blood*, **2014**, 124, 503-10	2.2	127
272	Regulation of microRNAs in cancer metastasis. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2014**, 1845, 255-65	11.2	109
271	Treatment recommendations for patients with Waldenstrm macroglobulinemia (WM) and related disorders: IWWM-7 consensus. *Blood*, **2014**, 124, 1404-11	2.2	107
270	Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. *Clinical Cancer Research*, **2012**, 18, 342-9	12.9	101
269	Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. *Blood*, **2014**, 124, 3250-9	2.2	98
268	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. *Cell Reports*, **2015**, 12, 622-35	10.6	94

267	SDF-1 inhibition targets the bone marrow niche for cancer therapy. *Cell Reports*, **2014**, 9, 118-128	10.6	93
266	The bone-marrow niche in MDS and MGUS: implications for AML and MM. *Nature Reviews Clinical Oncology*, **2018**, 15, 219-233	19.4	81
265	The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. *Blood*, **2014**, 124, 1765-76	2.2	80
264	The cancer glycome: carbohydrates as mediators of metastasis. *Blood Reviews*, **2015**, 29, 269-79	11.1	73
263	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. *Nature Cancer*, **2020**, 1, 493-506	15.4	73
262	TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrm's macroglobulinemia. *American Journal of Hematology*, **2016**, 91, 400-5	7.1	73
261	Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. *Lancet Oncology, The*, **2011**, 12, 263-72	21.7	72
260	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. *British Journal of Haematology*, **2018**, 182, 222-230	4.5	70
259	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. *Cell Reports*, **2017**, 19, 218-224	10.6	67
258	Mitochondrial metabolism promotes adaptation to proteotoxic stress. *Nature Chemical Biology*, **2019**, 15, 681-689	11.7	62
257	Role of endothelial progenitor cells in cancer progression. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2014**, 1846, 26-39	11.2	60
256	Central nervous system involvement by Waldenstrm macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. *British Journal of Haematology*, **2016**, 172, 709-15	4.5	60
255	Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. *Cell*, **2020**, 183, 1714-1731.e10	56.2	58
254	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. *Molecular Cancer Therapeutics*, **2018**, 17, 1454-1463	6.1	49
253	Pyk2 promotes tumor progression in multiple myeloma. *Blood*, **2014**, 124, 2675-86	2.2	48
252	Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. *Journal of Clinical Investigation*, **2018**, 128, 2487-2499	15.9	48
251	Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. *Bone*, **2015**, 75, 161-9	4.7	46
250	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. *Journal of Clinical Oncology*, **2020**, 38, 2380-2389	2.2	46

249	Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrm macroglobulinemia. *Blood*, **2013**, 121, 1296-303	2.2	45
248	Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E8425-E8432	11.5	45
247	Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstrm macroglobulinaemia. *British Journal of Haematology*, **2017**, 177, 717-725	4.5	44
246	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. *British Journal of Haematology*, **2015**, 169, 851-8	4.5	44
245	Triply Loaded Nitroxide Brush-Arm Star Polymers Enable Metal-Free Millimetric Tumor Detection by Magnetic Resonance Imaging. *ACS Nano*, **2018**, 12, 11343-11354	16.7	43
244	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. *British Journal of Haematology*, **2015**, 169, 843-50	4.5	42
243	Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenstrm Macroglobulinemia as a Paradigm. *Oncologist*, **2015**, 20, 1077-83	5.7	41
242	Genomic Landscape of Waldenstrm Macroglobulinemia and Its Impact on Treatment Strategies. *Journal of Clinical Oncology*, **2020**, 38, 1198-1208	2.2	40
241	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrm Macroglobulinemia. *Journal of Clinical Oncology*, **2021**, 39, 565-575	2.2	40
240	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 344-353	12.9	39
239	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. *Science Translational Medicine*, **2017**, 9,	17.5	36
238	Multiple Myeloma and the Immune Microenvironment. *Current Cancer Drug Targets*, **2017**, 17, 806-818	2.8	35
237	Monoclonal gammopathy of undetermined significance. *Blood*, **2019**, 133, 2484-2494	2.2	34
236	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. *Nature Communications*, **2020**, 11, 2996	17.4	34
235	Dissecting racial disparities in multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 19	7	34
234	Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. *Cancer Research*, **2016**, 76, 463-71	10.1	31
233	How I treat smoldering multiple myeloma. *Blood*, **2014**, 124, 3380-8	2.2	31
232	Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. *Journal of Molecular Diagnostics*, **2015**, 17, 669-78	5.1	30

231	A Prospective Multicenter Study Of The Brutons Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstroms Macroglobulinemia. *Blood*, **2013**, 122, 251-251	2.2	29
230	Current use of monoclonal antibodies in the treatment of multiple myeloma. *British Journal of Haematology*, **2018**, 181, 447-459	4.5	28
229	Global epigenetic regulation of microRNAs in multiple myeloma. *PLoS ONE*, **2014**, 9, e110973	3.7	28
228	CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. *Blood*, **2014**, 124, 1905-14	2.2	27
227	Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. *Clinical Cancer Research*, **2014**, 20, 3955-61	12.9	27
226	Are you sure this is Waldenstrm macroglobulinemia?. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 586-594	3.1	27
225	Platelets Enhance Multiple Myeloma Progression via IL-1Upregulation. *Clinical Cancer Research*, **2018**, 24, 2430-2439	12.9	26
224	Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. *Current Cancer Therapy Reviews*, **2014**, 10, 70-79	0.4	26
223	A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstrm Macroglobulinemia. *Clinical Cancer Research*, **2019**, 25, 4907-4916	12.9	25
222	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. *American Journal of Hematology*, **2019**, 94, 1244-1253	7.1	24
221	Exosomes in Tumor Angiogenesis. *Methods in Molecular Biology*, **2016**, 1464, 25-34	1.4	24
220	Targeting SDF-1 in multiple myeloma tumor microenvironment. *Cancer Letters*, **2016**, 380, 315-8	9.9	23
219	The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1283-1289	4	22
218	Genome instability in multiple myeloma. *Leukemia*, **2020**, 34, 2887-2897	10.7	22
217	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. *Leukemia*, **2018**, 32, 1739-1750	10.7	22
216	IgM myeloma: A multicenter retrospective study of 134 patients. *American Journal of Hematology*, **2017**, 92, 746-751	7.1	21
215	Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenstrm macroglobulinemia. *Molecular Cancer Research*, **2015**, 13, 263-72	6.6	21
214	Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. *Blood*, **2014**, 124, 34-34	2.2	21

213	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. *American Journal of Hematology*, **2017**, 92, 448-453	7.1	20
212	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. *Clinical Cancer Research*, **2019**, 25, 478-486	12.9	19
211	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. *Blood*, **2018**, 132, 2608-2612	2.2	19
210	Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. *Current Osteoporosis Reports*, **2017**, 15, 499-506	5.4	18
209	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). *Clinical Cancer Research*, **2017**, 23, 2400-2404	12.9	17
208	Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. *JCI Insight*, **2017**, 2,	9.9	17
207	Established and Novel Prognostic Biomarkers in Multiple Myeloma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 548-560	7.1	16
206	Are you sure this is Waldenstrom macroglobulinemia?. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 586-94	3.1	16
205	Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia. *Blood*, **2015**, 126, 1833-1833	2.2	16
204	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenstr□h macroglobulinemia. *Blood*, **2016**, 127, 2598-606	2.2	16
203	Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. *British Journal of Haematology*, **2017**, 176, 929-938	4.5	15
202	Dietary Pattern and Risk of Multiple Myeloma in Two Large Prospective US Cohort Studies. *JNCI Cancer Spectrum*, **2019**, 3, pkz025	4.6	15
201	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. *Blood*, **2018**, 132, 804-804	2.2	14
200	Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma. *Nanoscale*, **2019**, 11, 20485-20496	7.7	14
199	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 332-344	2	13
198	Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. *Blood*, **2014**, 124, 3483-3483	2.2	13
197	Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden. *Blood*, **2015**, 126, 119-119	2.2	13
196	Profiling of circulating exosomal miRNAs in patients with Waldenstr□h Macroglobulinemia. *PLoS ONE*, **2018**, 13, e0204589	3.7	13

195	Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. *Cytokine*, **2014**, 69, 294-7	4	11
194	ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?. *Hematology American Society of Hematology Education Program*, **2009**, 587-9	3.1	11
193	Fluorescence monitoring of rare circulating tumor cell and cluster dissemination in a multiple myeloma xenograft model in vivo. *Journal of Biomedical Optics*, **2019**, 24, 1-11	3.5	11
192	Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. *Blood*, **2011**, 118, 2951-2951	2.2	11
191	Prediagnosis dietary pattern and survival in patients with multiple myeloma. *International Journal of Cancer*, **2020**, 147, 1823-1830	7.5	10
190	Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.. *Nature Reviews Clinical Oncology*, **2022**,	19.4	10
189	Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. *Blood*, **2008**, 112, 3696-3696	2.2	10
188	Clinical Characteristics and Treatment Outcome Of CNS Involvement (Bing-Neel Syndrome) In Waldenstrom Macroglobulinemia. *Blood*, **2013**, 122, 5090-5090	2.2	10
187	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. *Blood*, **2015**, 126, 23-23	2.2	10
186	Pro-organic radical contrast agents ("pro-ORCAs") for real-time MRI of pro-drug activation in biological systems. *Polymer Chemistry*, **2020**, 11, 4768-4779	4.9	10
185	Genomic Aberrations in Multiple Myeloma. *Cancer Treatment and Research*, **2016**, 169, 23-34	3.5	10
184	Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All. *Cancers*, **2020**, 12,	6.6	9
183	Emerging drugs in multiple myeloma. *Expert Opinion on Emerging Drugs*, **2007**, 12, 155-63	3.7	9
182	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. *Leukemia Research*, **2020**, 98, 106459	2.7	9
181	Progression signature underlies clonal evolution and dissemination of multiple myeloma. *Blood*, **2021**, 137, 2360-2372	2.2	9
180	Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. *Leukemia*, **2019**, 33, 266-270	10.7	8
179	Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma. *Blood*, **2019**, 134, 3178-3178	2.2	8
178	Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. *American Journal of Hematology*, **2015**, 90, E122-3	7.1	7

177	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2015**, 126, 4217-4217	2.2	7
176	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. *Blood*, **2016**, 128, 197-197	2.2	7
175	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. *Blood*, **2021**, 138, 1535-1539	2.2	7
174	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. *American Journal of Hematology*, **2019**, 94, E146-E149	7.1	7
173	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. *Blood*, **2018**, 132, 749-749	2.2	6
172	Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstroms Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.. *Blood*, **2006**, 108, 2765-2765	2.2	6
171	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. *Blood*, **2008**, 112, 832-832	2.2	6
170	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. *Blood*, **2010**, 116, 3952-3952	2.2	6
169	Epigenetics in Multiple Myeloma. *Cancer Treatment and Research*, **2016**, 169, 35-49	3.5	6
168	Targeting the bone marrow in Waldenstrom macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11 Suppl 1, S65-9	2	5
167	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. *Blood*, **2010**, 116, 990-990	2.2	5
166	Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstroms Macroglobulinemia. *Blood*, **2013**, 122, 757-757	2.2	5
165	Single-cell RNA sequencing: one step closer to the clinic. *Nature Medicine*, **2021**, 27, 375-376	50.5	5
164	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. *Blood Advances*, **2019**, 3, 995-1002	7.8	5
163	Clinical perspective: Linking psychosocial care to the disease continuum in patients with multiple myeloma. *Palliative and Supportive Care*, **2015**, 13, 829-38	2.5	4
162	Finding the right academic job. *Hematology American Society of Hematology Education Program*, **2009**, 729-33	3.1	4
161	Novel therapeutic agents in Waldenström's macroglobulinemia. *Clinical Lymphoma and Myeloma*, **2009**, 9, 84-6		4
160	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. *Blood*, **2019**, 134, 4172-4172	2.2	4

159	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety. *Blood*, **2019**, 134, 1898-1898	2.2	4
158	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma. *Blood*, **2013**, 122, 1947-1947	2.2	4
157	Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma. *Blood*, **2014**, 124, 3431-3431	2.2	4
156	Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. *Blood*, **2015**, 126, 4256-4256	2.2	4
155	Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma. *Blood*, **2015**, 126, 502-502	2.2	4
154	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. *Blood Advances*, **2018**, 2, 1272-1276	7.8	4
153	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. *Clinical Cancer Research*, **2021**,	12.9	4
152	Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. *Leukemia and Lymphoma*, **2016**, 57, 2699-701	1.9	3
151	Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.. *Cancer Cell*, **2021**,	24.3	3
150	Serum Free Light Chain in Waldenstrom Macroglobulinemia.. *Blood*, **2006**, 108, 2420-2420	2.2	3
149	Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom Macroglobulinemia.. *Blood*, **2006**, 108, 2517-2517	2.2	3
148	In Vivo Mobilization of Multiple Myeloma Cells Out of the Bone Marrow Using the CXCR4 Inhibitor AMD3100 and Bortezomib: Implications for Sensitization of Myeloma Cells to Apoptosis.. *Blood*, **2007**, 110, 2501-2501	2.2	3
147	Lack of Response to Vaccination in MGUS and Stable Myeloma.. *Blood*, **2009**, 114, 1852-1852	2.2	3
146	Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis. *Blood*, **2010**, 116, 3051-3051	2.2	3
145	A Novel Activating Mutation Of CXCR4 Plays a Crucial Role In Waldenstrom Macroglobulinemia Biology. *Blood*, **2013**, 122, 272-272	2.2	3
144	Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia. *Blood*, **2013**, 122, 4402-4402	2.2	3
143	Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression. *Blood*, **2013**, 122, 680-680	2.2	3
142	Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia. *Blood*, **2014**, 124, 3081-3081	2.2	3

141	The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. *Oncotarget*, **2017**, 8, 35435-35444	3.3	3
140	Immunotherapy for hematological malignancies. *Journal of Life Sciences (Westlake Village, Calif)*, **2019**, 1, 46-52	1.9	3
139	A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. *American Journal of Hematology*, **2017**, 92, E138-E145	7.1	2
138	Aspirin Use and Survival in Multiple Myeloma Patients. *Blood*, **2018**, 132, 3250-3250	2.2	2
137	The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstroms Macroglobulinemia.. *Blood*, **2006**, 108, 2496-2496	2.2	2
136	The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).. *Blood*, **2007**, 110, 1516-1516	2.2	2
135	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. *Blood*, **2007**, 110, 4496-4496	2.2	2
134	RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia.. *Blood*, **2009**, 114, 3732-3732	2.2	2
133	Eph-B2/Ephrin-B2 Interaction Plays a Major Role In the Adhesion and Survival of WM Cells In the Context of the Bone Marrow Microenvironment. *Blood*, **2010**, 116, 142-142	2.2	2
132	Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma. *Blood*, **2010**, 116, 1943-1943	2.2	2
131	The New CXCR4 Inhibitor MDX-1338 Exerts Anti-Tumor Activity in Multiple Myeloma. *Blood*, **2011**, 118, 1844-1844	2.2	2
130	Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma. *Blood*, **2011**, 118, 625-625	2.2	2
129	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. *Blood*, **2016**, 128, 1137-1137	2.2	2
128	Prospective, Multicenter Clinical Trial of Everolimus As Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). *Blood*, **2016**, 128, 4487-4487	2.2	2
127	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. *Blood*, **2014**, 124, 5777-5777	2.2	2
126	Clinical Controversies in the Management of Smoldering Multiple Myeloma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2020**, 40, 1-6	7.1	2
125	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. *Blood Cancer Discovery*,OF1-OF12	7	2
124	Team work matters: dual inhibition puts non-hodgkin lymphoma under siege. *Clinical Cancer Research*, **2014**, 20, 5863-5	12.9	1

123	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. *Blood*, **2018**, 132, 2603-2603	2.2	1
122	Single-Cell Multi-Omics in Human Clonal Hematopoiesis Reveals That DNMT3A R882 Mutations Perturb Early Progenitor States through Selective Hypomethylation. *Blood*, **2020**, 136, 1-2	2.2	1
121	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. *Blood*, **2006**, 108, 3460-3460	2.2	1
120	Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM).. *Blood*, **2007**, 110, 1486-1486	2.2	1
119	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstro m Macroglobulinemia: Preliminary Results.. *Blood*, **2007**, 110, 4493-4493	2.2	1
118	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. *Blood*, **2008**, 112, 1011-1011	2.2	1
117	MicroRNA Changes Occur in Multiple Myeloma Cells in the Context of Bone Marrow Milieu.. *Blood*, **2009**, 114, 1785-1785	2.2	1
116	Role of Selectins in the Pathogenesis of Multiple Myeloma.. *Blood*, **2009**, 114, 951-951	2.2	1
115	The Role of Serum Immunoglobulin Free Light Chain In Response and Progression In Waldenstrom Macroglobulinemia. *Blood*, **2010**, 116, 3095-3095	2.2	1
114	Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and Sensitizes Them to Therapy. *Blood*, **2010**, 116, 453-453	2.2	1
113	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. *Blood*, **2011**, 118, 1874-1874	2.2	1
112	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. *Blood*, **2011**, 118, 2705-2705	2.2	1
111	Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. *Blood*, **2011**, 118, 2706-2706	2.2	1
110	Incidence of Peripheral Neuropathy in Waldenstro m Macroglobulinemia Patients At Diagnosis,. *Blood*, **2011**, 118, 3692-3692	2.2	1
109	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. *Blood*, **2011**, 118, 3966-3966	2.2	1
108	In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches. *Blood*, **2012**, 120, 440-440	2.2	1
107	Clonal-Heterogeneity and Propensity for Bone Metastasis in Multiple Myeloma. *Blood*, **2014**, 124, 3370-3370	2.2	1
106	Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma. *Blood*, **2021**, 138, 3044-3044	2.2	1

105	Single-Cell Multi-Omics Defines the Cell-Type Specific Impact of SF3B1 Splicing Factor Mutations on Hematopoietic Differentiation in Human Clonal Hematopoiesis and Myelodysplastic Syndromes. *Blood*, **2021**, 138, 145-145	2.2	1
104	Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease Pathology. *Blood*, **2021**, 138, 78-78	2.2	1
103	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma. *Blood*, **2021**, 138, 1649-1649	2.2	1
102	Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.. *Blood*, **2006**, 108, 2488-2488	2.2	1
101	Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.. *Blood*, **2009**, 114, 3752-3752	2.2	1
100	Hevylite , a New Marker of Tumor Measurement In Waldenstrom Macroglobulinemia. *Blood*, **2010**, 116, 5076-5076	2.2	1
99	BELLINI: a renaissance for an era of precision therapy in multiple myeloma. *Lancet Oncology, The*, **2020**, 21, 1547-1549	21.7	1
98	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. *Blood Cancer Discovery*, **2021**, 2, 338-353	7	1
97	Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, e400-6	7.1	1
96	Epigenomics in Waldenstrom's macroglobulinaemia. *Best Practice and Research in Clinical Haematology*, **2016**, 29, 156-160	4.2	1
95	Bone marrow niche in multiple myeloma and its precursor states.. *HemaSphere*, **2019**, 3,	0.3	1
94	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 27, 807-816		1
93	Intensification and consolidation therapy in multiple myeloma in the current era. *Lancet Haematology,the*, **2020**, 7, e427-e429	14.6	0
92	A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. *Blood*, **2021**, 138, 2749-2749	2.2	0
91	Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients. *Blood*, **2021**, 138, 1091-1091	2.2	0
90	Clonal Hematopoiesis Is Associated with Increased Risk of Progression of Asymptomatic Waldenstrm Macroglobulinemia. *Blood*, **2021**, 138, 2678-2678	2.2	0
89	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. *Blood*, **2018**, 132, 1981-1981	2.2	0
88	Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma. *Blood* , **2015**, 126, 1793-1793	2.2	0

87	Hypoxia Induces Drug Resistance In Multiple Myeloma. *Blood*, **2013**, 122, 1852-1852	2.2	0
86	Inflammatory stromal cells in the myeloma microenvironment. *Nature Immunology*, **2021**, 22, 677-678	19.1	0
85	Mass cytometry staining for human bone marrow clinical samples.. *STAR Protocols*, **2022**, 3, 101163	1.4	0
84	A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts. *Blood*, **2020**, 136, 1-2	2.2	
83	A Next Generation Liquid Biopsy Approach for Multiple Myeloma. *Blood*, **2020**, 136, 33-33	2.2	
82	Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. *Blood*, **2021**, 138, 4082-4082	2.2	
81	A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Low Risk Smoldering Multiple Myeloma. *Blood*, **2021**, 138, 1659-1659	2.2	
80	B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma. *Blood*, **2021**, 138, 4782-4782	2.2	
79	Single Cell Characterization of Myeloma and Its Precursor Conditions Reveals Transcriptional Signatures of Early Tumorigenesis. *Blood*, **2021**, 138, 2219-2219	2.2	
78	Identification of a Novel Epigenetic Mechanism of MYC Deregulation in Smoldering and Newly Diagnosed Multiple Myeloma Patients. *Blood*, **2021**, 138, 504-504	2.2	
77	Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstrom Macroglobulinemia, the Role of the ERK and PKC Pathways.. *Blood*, **2006**, 108, 2416-2416	2.2	
76	Imatinib Mesylate (Gleevec) Is Active in Relapsed/Refractory Waldenstrom Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-140.. *Blood*, **2006**, 108, 2484-2484	2.2	
75	The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia.. *Blood*, **2006**, 108, 2418-2418	2.2	
74	A Novel Real-Time In Vivo Homing Model of Multiple Myeloma.. *Blood*, **2006**, 108, 242-242	2.2	
73	Clinical and Pathological Prognostic Markers for Survival in Adult Patients with Post-Transplant Lymphoproliferative Disorders (PTLD), BCL2 Is a Poor Prognostic Marker in PTLD.. *Blood*, **2006**, 108, 2035-2035	2.2	
72	Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM).. *Blood*, **2007**, 110, 2512-2512	2.2	
71	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. *Blood*, **2007**, 110, 4494-4494	2.2	
70	The Interaction of CXCR4/SDF-1 and VLA-4 Regulates Adhesion and Transendothelial Migration in Waldenstrom Macroglobulinemia.. *Blood*, **2007**, 110, 2617-2617	2.2	

69	Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom Macroglobulinemia.. *Blood*, **2007**, 110, 1383-1383	2.2
68	Regulation of the New CXCR7 Receptor in Plasma Cell Dyscrasias.. *Blood*, **2007**, 110, 3527-3527	2.2
67	New Approaches to Multiple Myeloma. *European Oncology and Haematology*, **2018**, 14, 18	0.1
66	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. *Blood*, **2018**, 132, 3263-3263	2.2
65	Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule. *Blood*, **2018**, 132, 2024-2024	2.2
64	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. *Blood*, **2018**, 132, 55-55	2.2
63	Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM). *Blood*, **2018**, 132, 5664-5664	2.2
62	In Vivo Modeling of Clonal Competition Using CRISPR-Based Gene Editing Reveals Novel Fitness Variables in Multiple Myeloma. *Blood*, **2018**, 132, 57-57	2.2
61	Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis. *Blood*, **2019**, 134, 4341-4341	2.2
60	The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche. *Blood*, **2019**, 134, 507-507	2.2
59	MYC Overexpressing Multiple Myeloma Are Dependent on GLS1. *Blood*, **2019**, 134, 853-853	2.2
58	Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix. *Blood*, **2014**, 124, 2051-2051	2.2
57	Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells. *Blood*, **2014**, 124, 3430-3430	2.2
56	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM. *Blood*, **2014**, 124, 2101-2101	2.2
55	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. *Blood*, **2014**, 124, 2056-2056	2.2
54	MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma. *Blood*, **2015**, 126, 1755-1755	2.2
53	A New Model for Studying the Dissemination of Myeloma Cells throughout the Bone Marrow Using Embryonic Zebrafish. *Blood*, **2015**, 126, 915-915	2.2
52	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. *Blood*, **2015**, 126, 1770-1770	2.2

51	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. *Blood*, **2016**, 128, 237-237	2.2
50	Dual Conditional Loss of BLIMP-1 and p53 in B-Cells Drives B-Cell Lymphomagenesis. *Blood*, **2016**, 128, 4169-4169	2.2
49	In Vivo Analysis of Clonal Evolution of Multiple Myeloma. *Blood*, **2016**, 128, 799-799	2.2
48	Profiling of Circulating Exosomes in Patients with Waldenström Macroglobulinemia. *Blood*, **2016**, 128, 2940-2940	2.2
47	Identification of An Atypical Paraprotein with Inconsistent M-Spike Quantitation in Four Patients with Waldenström Macroglobulinemia. *Blood*, **2008**, 112, 5145-5145	2.2
46	The Effect of Insulin-Like Growth Factor 1 on Waldenstrom Macroglobulinemia. *Blood*, **2008**, 112, 4994-4994	2.2
45	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. *Blood*, **2008**, 112, 2737-2737	2.2
44	Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.. *Blood*, **2009**, 114, 2727-2727	2.2
43	Primary Waldesntrom Macroglobulinemia Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This Disease.. *Blood*, **2009**, 114, 3843-3843	2.2
42	Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM).. *Blood*, **2009**, 114, 3952-3952	2.2
41	Citron Rho Interacting Kinase (CRIK) Regulates Survival in IL-6 Dependent Multiple Myeloma Cells.. *Blood*, **2009**, 114, 1825-1825	2.2
40	Eph-B2 Receptor Tyrosine Kinase Is Overexpressed in Waldenstrom's Macroglubulinemia and Plays a Major Role in Its Interaction with the Bone Marrow Microenvironment.. *Blood*, **2009**, 114, 2935-2935	2.2
39	The Role of FGFR in the Progression of Waldenstrom's Macroglubulinemia and the Effect of Its Inhibition by TKI-258.. *Blood*, **2009**, 114, 3737-3737	2.2
38	The Effect of the CXCR4 Inhibitors, AMD3100 and AMD3465, in Multiple Myeloma Cell Homing and Its Interaction with the Bone Marrow Microenvironment.. *Blood*, **2009**, 114, 1826-1826	2.2
37	Selective Inhibition of the Chymotrypsin-Like Activity of the Immunoproteasome and Constitutive Proteasome Represents a Valid Anti-Tumor Strategy in Waldenstrom Macroglobulinemia.. *Blood*, **2009**, 114, 4911-4911	2.2
36	Carfilzomib Exerts Anti-Neoplastic Activity in Waldenstrom Macroglobulinemia.. *Blood*, **2009**, 114, 4916-4916	2.2
35	Role of Hypoxia in the Progression and Dissemination of Multiple Myeloma.. *Blood*, **2009**, 114, 421-421	2.2
34	PET/CT a New Marker of Response in Waldenstrom Macroglobulinemia (WM).. *Blood*, **2009**, 114, 1937-1937	2.2

33	Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.. *Blood*, **2009**, 114, 748-748	2.2
32	Genome Wide DNA Methylation Profiling In Patients with Multiple Myeloma.. *Blood*, **2010**, 116, 3622-3622	2.2
31	Dynamic Regulation of the Level of Hypoxia In the Bone Marrow Regulates Cell Dissemination In Multiple Myeloma. *Blood*, **2010**, 116, 4035-4035	2.2
30	Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma. *Blood*, **2010**, 116, 456-456	2.2
29	Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells. *Blood*, **2010**, 116, 2958-2958	2.2
28	LNA Anti-Microrna-155: a Novel Therapeutic Strategy In Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. *Blood*, **2010**, 116, 4914-4914	2.2
27	Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia. *Blood*, **2010**, 116, 3620-3620	2.2
26	The Role of PET Scan Imaging In Waldenstrom Macroglobulinemia. *Blood*, **2010**, 116, 4153-4153	2.2
25	Hypoxia Promotes Dissemination of Multiple Myeloma Through Acquisition of Endothelial to Mesenchymal Transition (EMT) Features. *Blood*, **2011**, 118, 471-471	2.2
24	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. *Blood*, **2011**, 118, 1409-1409	2.2
23	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. *Blood*, **2011**, 118, 815-815	2.2
22	The Role of PI3K Signaling in Cell Trafficking of Multiple Myeloma. *Blood*, **2011**, 118, 1804-1804	2.2
21	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,. *Blood*, **2011**, 118, 4134-4134	2.2
20	L-Stereoisomer RNA Oligonucleotide Anti-SDF-1 (Nox-A12) Disrupts the Interaction of Multiple Myeloma Cells with the Bone Marrow Milieu In Vivo, Leading to Enhanced Sensitivity to Bortezomib. *Blood*, **2011**, 118, 887-887	2.2
19	Role of TORC1 and TORC2 in Multiple Myeloma. *Blood*, **2011**, 118, 1815-1815	2.2
18	The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia. *Blood*, **2011**, 118, 2713-2713	2.2
17	MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia,. *Blood*, **2011**, 118, 3669-3669	2.2
16	Dissecting the role of CXCR7 in Cell Trafficking of Endothelial-Cells and Endothelial-Progenitor-Cells in Multiple Myeloma,. *Blood*, **2011**, 118, 3934-3934	2.2

List of Publications

15	LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. *Blood*, **2011**, 118, 2728-2728	2.2
14	Deregulation of TNFRSF18 (GITR) Through Promoter CpG Island Methylation Induces Tumor Proliferation in Multiple Myeloma. *Blood*, **2011**, 118, 2424-2424	2.2
13	Multiple Myeloma-Derived Bone-Marrow Mesenchymal Stem Cells: Microrna-, Gene Expression-Profiling and Functional Characterization. *Blood*, **2012**, 120, 1837-1837	2.2
12	CRM1 Inhibition Abrogates Osteoclast Formation and Bone Resorption Via Inhibition of RANKL-Induced NFB While Sparing Osteoblastogenesis: Further Therapeutic Implication in Multiple Myeloma. *Blood*, **2012**, 120, 1835-1835	2.2
11	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance in Multiple Myeloma. *Blood*, **2012**, 120, 3944-3944	2.2
10	Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma. *Blood*, **2012**, 120, 570-57	2.2
9	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression In Multiple Myeloma Through Modulation Of Wnt/Catenin Signaling Pathway. *Blood*, **2013**, 122, 3094-3094	2.2
8	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance In Multiple Myeloma. *Blood*, **2013**, 122, 121-121	2.2
7	Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients. *Blood*, **2013**, 122, 3086-3086	2.2
6	Class I PI3K Isoforms Exert a Differential Role On Survival and Cell Trafficking In Multiple Myeloma. *Blood*, **2013**, 122, 3159-3159	2.2
5	Extramedullary Disease In Waldenstrom Macroglobulinemia. *Blood*, **2013**, 122, 1773-1773	2.2
4	A Case-Control Epidemiological Study Of Waldenstrom Macroglobulinemia. *Blood*, **2013**, 122, 1713-1713	2.2
3	Methylation-Dependent Epigenetic Silencing Of Mir-152 and Mir-10b-5p Plays a Crucial Role In Modulating Tumor Progression In Multiple Myeloma. *Blood*, **2013**, 122, 3751-3751	2.2
2	Microrna-Dependent Modulation Of Osteogenesis In a 3D In Vitro Bone Marrow Model System Of Multiple Myeloma. *Blood*, **2013**, 122, 3093-3093	2.2
1	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. *Journal of Clinical Oncology*, **2021**, 39, 12082-12082	2.2